Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective
The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
Abstract
Several regulatory guidances on the use of physiologically based pharmacokinetic (PBPK) analyses and physiologically based biopharmaceutics model(s) (PBBM(s)) have been issued. Workshops are routinely held, demonstrating substantial interest in applying these modeling approaches to address scientific questions in drug development. PBPK models and PBBMs have remarkably contributed to model-informed drug development (MIDD) such as anticipating clinical PK outcomes affected by extrinsic and intrinsic factors in general and specific populations. In this review, we proposed practical considerations for a "base" PBPK model construction and development, summarized current status, challenges including model validation and gaps in system models, and future perspectives in PBPK evaluation to assess a) drug metabolizing enzyme(s)- or drug transporter(s)- mediated drug-drug interactions b) dosing regimen prediction, sampling timepoint selection and dose validation in pediatric patients from newborns to adolescents, c) drug exposure in patients with renal and/or and hepatic organ impairment, d) maternal-fetal drug disposition during pregnancy, and e) pH-mediated drug-drug interactions in patients treated with proton pump inhibitors/acid-reducing agents (PPIs/ARAs) intended for gastric protection. Since PBPK can simulate outcomes in clinical studies with enrollment challenges or ethical issues, the impact of PBPK models on waivers and how to strengthen study waiver is discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Terfenadine is also the canonical example that PBPK platforms now explicitly address through metabolite-linked parent models and DDI simulations [22,84,85].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [84]
In the citing paper
“and predictivity for poorly soluble, formulation-sensitive compounds depends heavily on the quality of dissolution and precipitation modelling inputs [12,84,91].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [84]
In the citing paper
“overparameterization may yield apparent good fits without genuine predictive validity;”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [84]
In the citing paper
“uncertainty propagation through complex models can produce confidence intervals that under-represent true predictive uncertainty;”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [84]
In the citing paper
“Regulatory acceptance varies by intended impact: supportive PBPK contextualizing other data is widely accepted; decision-enabling PBPK that drives dose recommendations or DDI labelling demands closer scrutiny; and label-replacing PBPK substituting for dedicated clinical studies remains the most stringently reviewed category, restricted to thoroughly verified contexts of use [22,84,85].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [84]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
Onset of Maternal Arterial Blood Flow and Placental Oxidative Stress
Jauniaux, E., Watson, A. L., Hempstock, J., Bao, Y.-P., Skepper, J. N., & Burton, G. J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64849-3 · Cited by 1,057
Pharmacokinetics and dosage adjustment in patients with renal dysfunction
Verbeeck, R. K., & Musuamba, F. T. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0678-8 · Cited by 717
Assessment of the prognosis of cirrhosis: Child–Pugh versus MELD
Durand, F., & Valla, D. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.11.015 · Cited by 656
Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction
Verbeeck, R. K. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0553-z · Cited by 652
Pregnancy-Induced Changes in Pharmacokinetics: A Mechanistic-Based Approach
Anderson, G. D. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544100-00001 · Cited by 648
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 545
Johnson, T. N., Rostami-Hodjegan, A., & Tucker, G. T. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645090-00005 · Cited by 530
Sager, J. E., Yu, J., Ragueneau-Majlessi, I., & Isoherranen, N. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065920 · Cited by 518
Jones, H., Chen, Y., Gibson, C., Heimbach, T., Parrott, N., Peters, S., Snoeys, J., Upreti, V., Zheng, M., & Hall, S. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.37 · Cited by 488 · cited 1×
“There is limited experience in IVIVE and PBPK modeling for nonCYP enzymes (such as, UDP-glucuronosyltransferases (UGTs), sulfotransferases (SULTs), carboxylesterases (CESs), and aldehyde oxidase (AO)) while case examples are emerging (21, 22, 164).”
BackgroundSelf-citationClinical pharmacology and therapeutics
Fenn, G. C. (1990) · Postgraduate Medical Journal · doi:10.1136/pgmj.66.778.686 · Cited by 479
Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy
Tracy, T. S., Venkataramanan, R., Glover, D. D., & Caritis, S. N. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.08.030 · Cited by 448
Shebley, M., Sandhu, P., Emami Riedmaier, A., Jamei, M., Narayanan, R., Patel, A., Peters, S. A., Reddy, V. P., Zheng, M., de Zwart, L., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1013 · Cited by 395 · cited 1×
“optimization of clinical trial design, clinical PK data interpretation and inference, and reduction of unnecessary clinical studies (6, 7).”
BackgroundSelf-citationDevelopmental Changes in Pharmacokinetics and Pharmacodynamics
van den Anker, J., Reed, M. D., Allegaert, K., & Kearns, G. L. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1284 · Cited by 389
Workgroup, E. M., Marshall, S., Burghaus, R., Cosson, V, Cheung, S., Chenel, M., DellaPasqua, O., Frey, N., Hamrén, B., Harnisch, L., et al. (2016) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12049 · Cited by 373
Abduljalil, K., Furness, P., Johnson, T. N., Rostami-Hodjegan, A., & Soltani, H. (2012) · Clinical Pharmacokinetics · doi:10.2165/11597440-000000000-00000 · Cited by 371 · cited 1×
“Although some information is available about in vivo changes in major maternal CYP enzyme activity in the 3rd trimester (T3) (86, 91, 93), such information is lacking for T1 and T2, and throughout pregnancy for minor CYP enzymes (e.”
BackgroundUpper Gastrointestinal pH in Seventy-Nine Healthy, Elderly, North American Men and Women
Russell, T. L., Berardi, R. R., Barnett, J. L., Dermentzoglou, L. C., Jarvenpaa, K. M., Schmaltz, S. P., & Dressman, J. B. (1993) · Pharmaceutical Research · doi:10.1023/a:1018970323716 · Cited by 367
Hustin, J., & Schaaps, J.-P. (1987) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(87)80371-x · Cited by 346
Budha, N. R., Frymoyer, A., Smelick, G. S., Jin, J. Y., Yago, M. R., Dresser, M. J., Holden, S. N., Benet, L. Z., & Ware, J. A. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.73 · Cited by 338
Garg, A., & Balthasar, J. P. (2007) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-007-9065-1 · Cited by 327
Grimstein, M., Yang, Y., Zhang, X., Grillo, J., Huang, S.-M., Zineh, I., & Wang, Y. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.10.033 · Cited by 317
Self-citationWagner, C., Zhao, P., Pan, Y., Hsu, V, Grillo, J., Huang, S., & Sinha, V (2015) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.33 · Cited by 276
Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders
Shahryari, A., Saghaeian Jazi, M., Mohammadi, S., Razavi Nikoo, H., Nazari, Z., Hosseini, E. S., Burtscher, I., Mowla, S. J., & Lickert, H. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00868 · Cited by 262
Hebert, M., Easterling, T., Kirby, B., Carr, D., Buchanan, M., Rutherford, T., Thummel, K., Fishbein, D., & Unadkat, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.1 · Cited by 259
Self-citationTsamandouras, N., Rostami‐Hodjegan, A., & Aarons, L. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12234 · Cited by 250
Jamei, M. (2016) · Current Pharmacology Reports · doi:10.1007/s40495-016-0059-9 · Cited by 244
A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance
Johnson, T. N., Boussery, K., Rowland-Yeo, K., Tucker, G. T., & Rostami-Hodjegan, A. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318160-000000000-00000 · Cited by 235
Zhao, P., Rowland, M., & Huang, S.-M. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.68 · Cited by 212
Ring, B. J., Chien, J. Y., Adkison, K. K., Jones, H. M., Rowland, M., Jones, R. D., Yates, J. W. T., Ku, M. S., Gibson, C. R., He, H., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22552 · Cited by 206
Effect of gastric acid suppressants on human gastric motility
Parkman, H. P., Urbain, J.-L. C., Knight, L. C., Brown, K. L., Trate, D. M., Miller, M. A., Maurer, A. H., & Fisher, R. S. (1998) · Gut · doi:10.1136/gut.42.2.243 · Cited by 201
Jänne, P. A., Boss, D. S., Camidge, D. R., Britten, C. D., Engelman, J. A., Garon, E. B., Guo, F., Wong, S., Liang, J., Letrent, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1220 · Cited by 181
Zhang, X., Yang, Y., Grimstein, M., Fan, J., Grillo, J. A., Huang, S., Zhu, H., & Wang, Y. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1767 · Cited by 181
Self-citationKuemmel, C., Yang, Y., Zhang, X., Florian, J., Zhu, H., Tegenge, M., Huang, S., Wang, Y., Morrison, T., & Zineh, I. (2020) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12479 · Cited by 177
Self-citationHanke, N., Frechen, S., Moj, D., Britz, H., Eissing, T., Wendl, T., & Lehr, T. (2018) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12343 · Cited by 169 · cited 1×
“In addition, each pathway needs to be assessed both individually and in combination (50).”
BackgroundUpreti, V. V., & Wahlstrom, J. L. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.585 · Cited by 165
Antimalarial Drugs in Pregnancy: A Review
Nosten, F., McGready, R., d'Alessandro, U., Bonell, A., Verhoeff, F., Menendez, C., Mutabingwa, T., & Brabin, B. (2006) · Current Drug Safety · doi:10.2174/157488606775252584 · Cited by 164
Physiologically-based pharmacokinetic models for children: Starting to reach maturation?
Verscheijden, L. F. M., Koenderink, J. B., Johnson, T. N., de Wildt, S. N., & Rüssel, F. G. M. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107541 · Cited by 163
Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies
Cao, Y., Balthasar, J. P., & Jusko, W. J. (2013) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-013-9332-2 · Cited by 161
Tomson, T., Lindbom, U., Ekqvist, B., & Sundqvist, A. (1994) · Epilepsia · doi:10.1111/j.1528-1157.1994.tb02921.x · Cited by 161
Bonner, J. J., Vajjah, P., Abduljalil, K., Jamei, M., Rostami‐Hodjegan, A., Tucker, G. T., & Johnson, T. N. (2015) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1937 · Cited by 159
Taskar, K. S., Reddy, V. P., Burt, H. J., Posada, M. M., Varma, M. V. S., Zheng, M., Ullah, M., Riedmaier, A. E., Umehara, K., Snoeys, J., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1693 · Cited by 157
Self-citationJones, R. D. O., Jones, H. M., Rowland, M., Gibson, C. R., Yates, J. W. T., Chien, J. Y., Ring, B. J., Adkison, K. K., Ku, M. S., He, H., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22553 · Cited by 153
Allen, H. C., Garbe, M. C., Lees, J., Aziz, N., Chaaban, H., Miller, J. L., Johnson, P. N., & DeLeon, S. D. (2018) · PubMed · Cited by 152
Heimbach, T., Chen, Y., Chen, J., Dixit, V. S., Parrott, N. J., Peters, S. A., Poggesi, I., Sharma, P. K., Snoeys, J., Shebley, M., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2125 · Cited by 147
Self-citationMiller, N. A., Reddy, M. B., Heikkinen, A. T., Lukacova, V., & Parrott, N. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00741-9 · Cited by 142 · cited 7×
“Once the base PBPK model is constructed, it can predict drug PK in FIH study and consequently, be extrapolated for a number of projections, e.g., DDI, OI, and pediatrics.”
MethodInfluentialZhang, X., Lionberger, R. A., Davit, B. M., & Yu, L. X. (2011) · The AAPS Journal · doi:10.1208/s12248-010-9250-9 · Cited by 136
Self-citationScaffidi, J., Mol, B. W., & Keelan, J. A. (2016) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.14151 · Cited by 132
Salem, F., Johnson, T. N., Abduljalil, K., Tucker, G. T., & Rostami-Hodjegan, A. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0140-7 · Cited by 128
Ke, A. B., Nallani, S. C., Zhao, P., Rostami‐Hodjegan, A., & Unadkat, J. D. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12207 · Cited by 124
Self-citationPregnancy-induced increase in metoprolol metabolism
Högstedt, S., Lindberg, B., Peng, D. R., Regårdh, C.-G., & Rane, A. (1985) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1985.114 · Cited by 124
Bhatt, D. K., Mehrotra, A., Gaedigk, A., Chapa, R., Basit, A., Zhang, H., Choudhari, P., Boberg, M., Pearce, R. E., Gaedigk, R., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1109 · Cited by 123
van Leeuwen, R. W. F., Peric, R., Hussaarts, K. G. A. M., Kienhuis, E., IJzerman, N. S., de Bruijn, P., van der Leest, C., Codrington, H., Kloover, J. S., van der Holt, B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.2560 · Cited by 122
El‐Khateeb, E., Burkhill, S., Murby, S., Amirat, H., Rostami‐Hodjegan, A., & Ahmad, A. (2021) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2257 · Cited by 122
Chen, Y., Jin, J. Y., Mukadam, S., Malhi, V., & Kenny, J. R. (2012) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1769 · Cited by 113
Self-citationEley, T., Luo, F., Agrawal, S., Sanil, A. P., Manning, J., Li, T., Blackwood‐Chirchir, A., & Bertz, R. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009333854 · Cited by 113
Mitra, A., & Kesisoglou, F. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400256h · Cited by 108 · cited 1×
“The absorption rate and extent can be reduced due to less favorable solubility/dissolution at higher gastric pH values resulting from administration of ARA/PPI (122) or due to achlorhydria (123, 124).”
BackgroundMyllynen, P., Immonen, E., Kummu, M., & Vähäkangas, K. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903304049 · Cited by 106
Zhang, Z., Imperial, M. Z., Patilea-Vrana, G., Wedagedera, J. R., Gaohua, L., & Unadkat, J. D. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.075192 · Cited by 106
Self-citationGreenberg, R. G., Gamel, B., Bloom, D. L., Bradley, J. S., Jafri, H. S., Hinton, D., Nambiar, S., Wheeler, C., Tiernan, R., Smith, P. B., et al. (2017) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2017.11.005 · Cited by 102
Almond, L. M., Mukadam, S., Gardner, I., Okialda, K., Wong, S., Hatley, O., Tay, S., Rowland-Yeo, K., Jamei, M., Rostami-Hodjegan, A., et al. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.066845 · Cited by 101
Zhang, Z., & Unadkat, J. D. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.073957 · Cited by 98
Self-citationvan den Anker, J. N., McCune, S., Annaert, P., Baer, G., Mulugeta, Y. A., Abdelrahman, R. A., Wu, K., Krudys, K. M., Fisher, J. W., Slikker, W., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070685 · Cited by 97
Ke, A. B., Nallani, S. C., Zhao, P., Rostami‐Hodjegan, A., Isoherranen, N., & Unadkat, J. D. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.050161 · Cited by 96
Self-citationGrillo, J. A., Zhao, P., Bullock, J., Booth, B. P., Lu, M., Robie‐Suh, K., Berglund, E. G., Pang, K. S., Rahman, A., Zhang, L., et al. (2012) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1771 · Cited by 93
Clinical Pharmacokinetic and Pharmacodynamic Profile of Etoricoxib
Takemoto, J. K., Reynolds, J. K., Remsberg, C. M., Vega‐Villa, K. R., & Davies, N. M. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847110-00002 · Cited by 93
Ke, A., Nallani, S., Zhao, P., Rostami‐Hodjegan, A., & Unadkat, J. (2012) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2012.2 · Cited by 93
Self-citationZhang, H., Wu, X., Wang, H., Mikheev, A. M., Mao, Q., & Unadkat, J. D. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.043851 · Cited by 93
Self-citationCharacterization of Differential Tissue Abundance of Major Non-CYP Enzymes in Human
Basit, A., Neradugomma, N. K., Wolford, C. C., Fan, P. W., Murray, B. P., Takahashi, R., Khojasteh, S. C., Smith, B. J., Heyward, S. A., Totah, R. A., et al. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00559 · Cited by 92
Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence
Rostami‐Hodjegan, A. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.904 · Cited by 90
Tang, H., & Mayersohn, M. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20481 · Cited by 89
Achour, B., Al‐Majdoub, Z. M., Grybos‐Gajniak, A., Lea, K., Kilford, P. J., Zhang, M., Knight, D., Barber, J., Schageman, J. J., & Rostami‐Hodjegan, A. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2102 · Cited by 89
Hsueh, C., Hsu, V., Zhao, P., Zhang, L., Giacomini, K. M., & Sm, H. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.750 · Cited by 87
Disposition of Carbamazepine and Phenytoin in Pregnancy
Tomson, T., Lindbom, U., Ekqvist, B., & Sundqvist, A. (1994) · Epilepsia · doi:10.1111/j.1528-1157.1994.tb02922.x · Cited by 86
Yin, O. Q. P., Gallagher, N. J., Fischer, D., Demirhan, E., Zhou, W., Golor, G., & SCHRAN, H. F. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009346061 · Cited by 85
Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine
Kletzl, H., Giraudon, M., Ducray, P. S., Abt, M., Hamilton, M., & Lum, B. L. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000212 · Cited by 85
Samant, T. S., Dhuria, S., Lu, Y., Laisney, M., Yang, S., Grandeury, A., Mueller‐Zsigmondy, M., Umehara, K., Huth, F., Miller, M., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.940 · Cited by 82
Sun, W., Klamerus, K. J., Yuhas, L. M., Pawlak, S., Plotka, A., O’Gorman, M. T., Kirkovsky, L., Kosa, M. B., & Wang, D. (2017) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.356 · Cited by 82
Anoshchenko, O., Prasad, B., Neradugomma, N. K., Wang, J., Mao, Q., & Unadkat, J. D. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000067 · Cited by 79
Self-citationEl‐Khateeb, E., Achour, B., Al‐Majdoub, Z. M., Barber, J., & Rostami‐Hodjegan, A. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00462 · Cited by 79
Parrott, N. J., Yu, L. J., Takano, R., Nakamura, M., & Morcos, P. N. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9957-3 · Cited by 77
Badée, J., Qiu, N., Collier, A. C., Takahashi, R., Forrest, W. F., Parrott, N. J., Schmidt, S., & Fowler, S. M. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1493 · Cited by 76
Numico, G., Fusco, V., Franco, P., & Roila, F. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.014 · Cited by 74
Monine, M. I., Norris, D. A., Wang, Y., & Nestorov, I. A. (2021) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-021-09761-0 · Cited by 72
Miller, B. E., Mistry, S. J., Smart, K. A., Connolly, P., Carpenter, D. C., Cooray, H., Bloomer, J. C., Tal‐Singer, R., & Lazaar, A. L. (2015) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-015-0017-x · Cited by 70
Wu, F. P., Shah, H., Li, M., Duan, P., Zhao, P., Suarez, S., Raines, K., Zhao, Y., Wang, M., Lin, H.-P., et al. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00564-2 · Cited by 70
Heimbach, T., Kesisoglou, F., Novaković, J., Tistaert, C., Mueller‐Zsigmondy, M., Kollipara, S., Ahmed, T., Mitra, A., & Suarez‐Sharp, S. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.09.017 · Cited by 70
Self-citationEffect of a proton pump inhibitor on the pharmacokinetics of imatinib
Egorin, M. J., Shah, D. D., Christner, S. M., Yerk, M., Komazec, K. A., Appleman, L. J., Redner, R. L., Miller, B. M., & Beumer, J. H. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03466.x · Cited by 69
Mendes, M. D. S., Lui, G., Zheng, Y., Pressiat, C., Hirt, D., Valade, E., Bouazza, N., Foissac, F., Blanche, S., Tréluyer, J., et al. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0457-5 · Cited by 68
El‐Khateeb, E., Darwich, A. S., Achour, B., Athwal, V. S., & Rostami‐Hodjegan, A. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16489 · Cited by 68
Li, L., Gardner, I. B., Dostálek, M., & Jamei, M. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9640-5 · Cited by 67
Visscher, M., & Narendran, V. (2014) · Advances in Wound Care · doi:10.1089/wound.2013.0467 · Cited by 66
In silico Prediction of Total Human Plasma Clearance
Berellini, G., Waters, N. J., & Lombardo, F. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300155y · Cited by 65
Tan, M., Zhao, P., Zhang, L., Ho, Y., Varma, M. V. S., Neuhoff, S., Nolin, T. D., Galetin, A., & Huang, S. M. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1205 · Cited by 64
Re, M. D., Omarini, C., Diodati, L., Palleschi, M., Meattini, I., Crucitta, S., Lorenzini, G., Isca, C., Fontana, A., Livi, L., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100231 · Cited by 63
Murad, N., Pasikanti, K. K., Madej, B. D., Minnich, A., McComas, J., Crouch, S., Polli, J. W., & Weber, A. D. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000202 · Cited by 62
Schalkwijk, S. J., Buaben, A. O., Freriksen, J. J. M., Colbers, A. P. H., Burger, D. M., Greupink, R., & Rüssel, F. G. M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0583-8 · Cited by 59
Mitra, A., Parrott, N. J., Miller, N. A., Lloyd, R. S., Tistaert, C., Heimbach, T., Ji, Y., & Kesisoglou, F. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.11.017 · Cited by 59
Self-citationEffects of Pregnancy on the Pharmacokinetics of Metformin
Liao, M. Z., Flood-Nichols, S. K., Ahmed, M., Clark, S. M., Hankins, G. D. V., Caritis, S. N., Venkataramanan, R., Haas, D. M., Quinney, S. K., Haneline, L. S., et al. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.088435 · Cited by 59
Morcos, P. N., Guerini, E., Parrott, N. J., Dall, G., Blotner, S. D., Bogman, K., Sturm, C., Balas, B. I., Martin‐Facklam, M., & Phipps, A. (2016) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.296 · Cited by 58
Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds
Zhang, T., Heimbach, T., Lin, W., Zhang, J., & He, H. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24373 · Cited by 56 · cited 1×
“(20) described the mechanism-based absorption prediction method outperformed an alternate method using the average preclinical bioavailability (F) and absorption rate constant (ka) values for a number of molecules.”
MethodSelf-citationAbduljalil, K., Jamei, M., & Johnson, T. N. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0685-y · Cited by 56
Badée, J., Fowler, S. M., de Wildt, S. N., Collier, A. C., Schmidt, S., & Parrott, N. J. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0681-2 · Cited by 55
Effect of antacid on imatinib absorption
Sparano, B. A., Egorin, M. J., Parise, R. A., Walters, J., Komazec, K. A., Redner, R. L., & Beumer, J. H. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0778-7 · Cited by 54
Pepin, X. J. H., Moir, A. J., Mann, J., Sanderson, N. J., Barker, R., Meehan, E. J., Plumb, A. P., Bailey, G. R., Murphy, D. S., Krejsa, C. M., et al. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.07.011 · Cited by 54
Costales, C., Lin, J., Kimoto, E., Yamazaki, S., Gosset, J. R., Rodrigues, A. D., Lazzaro, S., West, M. A., West, M., & Varma, M. V. S. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12672 · Cited by 54
Xia, B., Heimbach, T., He, H., & Lin, T. (2012) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1821 · Cited by 52
Self-citationImpact of Inflammation on Cytochromes P450 Activity in Pediatrics: A Systematic Review
Lenoir, C., Rodieux, F., Desmeules, J. A., Rollason, V., & Samer, C. F. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01064-4 · Cited by 50
Ayyar, V. S., Song, D., Zheng, S., Carpenter, T., & Heald, D. L. (2021) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000805 · Cited by 49
Coppola, P., Ghazaly, E. A., & Cole, S. M. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.687978 · Cited by 48
Vaidhyanathan, S., Wang, X., Crison, J. R., Varia, S. A., Gao, J., Saxena, A., & Good, D. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.11.005 · Cited by 47
Pan, X., Stader, F., Abduljalil, K., Gill, K. L., Johnson, T. N., Gardner, I. B., & Jamei, M. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00460-1 · Cited by 47
Dong, Z., Li, J., Wu, F. P., Zhao, P., Lee, S., Zhang, L., Seo, P., & Zhang, L. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12541 · Cited by 46
Cleary, Y., Gertz, M., Grimsey, P., Günther, A., Heinig, K., Ogungbenro, K., Aarons, L. J., Galetin, A., & Kletzl, H. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2384 · Cited by 46
Methodological Approaches to Evaluate Fetal Drug Exposure
Bouazza, N., Foissac, F., Hirt, D., Urien, S., Benaboud, S., Lui, G., & Tréluyer, J. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190319102812 · Cited by 45
Smits, A., Cock, P. A. J. G. D., Vermeulen, A., & Allegaert, K. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1558205 · Cited by 43
Anoshchenko, O., Storelli, F., & Unadkat, J. D. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000538 · Cited by 43
Self-citationJorga, K. M., Chavanne, C., Frey, N., Lavé, T., Lukacova, V., Parrott, N. J., Peck, R., & Reigner, B. G. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.449 · Cited by 42
Freriksen, J. J. M., Schalkwijk, S. J., Colbers, A. P. H., Abduljalil, K., Rüssel, F. G. M., Burger, D. M., & Greupink, R. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1748 · Cited by 42
Ono, C., Hsyu, P., Abbas, R., Loi, C., & Yamazaki, S. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074450 · Cited by 41
Marsousi, N., Desmeules, J. A., Rudaz, S. L., & Daali, Y. (2017) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2107 · Cited by 41
Prediction of ARA/PPI Drug-Drug Interactions at the Drug Discovery and Development Interface
Dodd, S., Kollipara, S., Sánchez-Félix, M., Kim, H., Meng, Q., Beato, S., & Heimbach, T. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.10.032 · Cited by 40
Self-citationSalehi, N., Kuminek, G., Al-Gousous, J., Sperry, D. C., Greenwood, D. E., Waltz, N. M., Amidon, G. L., Ziff, R. M., & Amidon, G. E. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00262 · Cited by 40
Villiger, A., Stillhart, C., Parrott, N. J., & Kuentz, M. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9896-z · Cited by 39
Abbas, R., Leister, C. A., & Sonnichsen, D. S. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0103-z · Cited by 38
Bergagnini‐Kolev, M. C., Hébert, M. F., Easterling, T. R., & Lin, Y. S. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.073841 · Cited by 38
Barrett, J. S., Bishai, R., Bucci‐Rechtweg, C., Cheung, A., Corriol‐Rohou, S., Haertter, S., James, A., Kovacs, S. J., Liu, J., Potempa, D., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1000 · Cited by 38
Jean, D., Naik, K., Milligan, L., Hall, S. D., Huang, S. M., Isoherranen, N., Kuemmel, C., Seo, P., Tegenge, M. A., Wang, Y., et al. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12706 · Cited by 38
Self-citationHuth, F., Gardin, A., Umehara, K., & He, H. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1547 · Cited by 37
Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects
Keyvanjah, K., DiPrimeo, D., Li, A., Obaidi, M., Swearingen, D., & Wong, A. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13132 · Cited by 35
Johnson, D. A., STACY, T., Ryan, M. J., Wootton, T., Willis, J., Hornbuckle, K., Brooks, W. D., & DOVIAK, M. J. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02534.x · Cited by 34
Einolf, H. J., Lin, W., Won, C. S., Wang, L., Gu, H., Chun, D. Y., He, H., & Mangold, J. B. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.076851 · Cited by 34
Self-citationFrechen, S., Solodenko, J., Wendl, T., Dallmann, A., Ince, I., Lehr, T., Lippert, J., & Burghaus, R. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12636 · Cited by 32
Ontogeny of Drug-Metabolizing Enzymes
Thakur, A., Parvez, M. M., Leeder, J. S., & Prasad, B. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1554-6_18 · Cited by 32
Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients
Koch, K. M., Im, Y., Kim, S., Urruticoechea, A., Stephenson, J., Botbyl, J. D., Cartee, L., Holshouser, J., & Ridgway, D. (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.45 · Cited by 31
Yokota, H., Sato, K., Okuda, Y., Kobayashi, H., Takeda, M., Asano, M., Ito, H., & Miura, M. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.05.010 · Cited by 31
Biliouris, K., Gaitonde, P., Yin, W., Norris, D. A., Wang, Y., Henry, S. P., Fey, R. A., Nestorov, I. A., Schmidt, S., Rogge, M. C., et al. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12323 · Cited by 31
Heimbach, T., Lin, W., Hourcade‐Potelleret, F., Tian, X., Combes, F. P., Horvath, N. M., & He, H. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.01.028 · Cited by 31
Self-citationPeng, J., Ladumor, M. K., & Unadkat, J. D. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000557 · Cited by 31
Self-citationJohnson, T. N., & Ke, A. B. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1834 · Cited by 30
Tang, F., Wong, H. H., & Ng, C. M. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2269 · Cited by 29
Clinical pharmacology. Drug development.
George, C. F. (1980) · BMJ · doi:10.1136/bmj.281.6252.1397 · Cited by 28
Lin, W., Heimbach, T., Jain, J. P., Awasthi, R., Hamed, K. A., Sunkara, G., & He, H. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.06.026 · Cited by 28
Self-citationRuiz-García, A., Masters, J. C., da Costa, L. M., LaBadie, R. R., Liang, Y., Ni, G., Ellery, C. A., Boutros, T., Goldberg, Z., & Bello, C. L. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.588 · Cited by 27
Bergman, A. J., Bi, Y., Mathialagan, S., Litchfield, J., Kazierad, D. J., Pfefferkorn, J. A., & Varma, M. V. S. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1419 · Cited by 27
Filppula, A. M., Parvizi, R., Mateus, A., Baranczewski, P., & Artursson, P. (2019) · Scientific Reports · doi:10.1038/s41598-019-42051-x · Cited by 27
Berellini, G., & Lombardo, F. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.088914 · Cited by 27
Callegari, E., Lin, J., Tse, S., Goosen, T. C., & Sahasrabudhe, V. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12581 · Cited by 27
Kanacher, T., Lindauer, A., Mezzalana, E., Michon, I. N., Veau, C., Gómez‐Mantilla, J. D., Nock, V., & Fleury, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121191 · Cited by 27
Gajewska, M., Blumenstein, L., Kourentas, A., Mueller‐Zsigmondy, M., Lorenzo, S., Sinn, A., Velinova, M. J., & Heimbach, T. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00511-7 · Cited by 25
Self-citationBloomer, J. C., Ambery, C. L., Miller, B. E., Connolly, P., Garden, H., Henley, N., Hodnett, N. S., Keel, S., Kreindler, J. L., Lloyd, R. S., et al. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.03.023 · Cited by 24
Evaluation of Model‐Based Prediction of Pharmacokinetics in the Renal Impairment Population
Yee, K. L., Li, M., Cabalu, T. D., Sahasrabudhe, V., Lin, J., Zhao, P., & Jadhav, P. R. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1022 · Cited by 24
Yamazaki, S., Loi, C., Kimoto, E., Costales, C., & Varma, M. V. S. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.080424 · Cited by 24
Chirumamilla, S. K., Banala, V. T., Jamei, M., & Turner, D. B. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081169 · Cited by 24
Lau, Y. Y., Gu, W., Lin, T., Viraswami-Appanna, K., Cai, C., Scott, J. W., & Shi, M. M. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3308-7 · Cited by 23
Sychterz, C. J., Galetin, A., & Taskar, K. S. (2021) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2272 · Cited by 21
Renal failure in cirrhosis: Emerging concepts
Bittencourt, P. L. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i21.2336 · Cited by 20
Ruiz-García, A., Tan, W., Li, J., Haughey, M., Masters, J. C., Hibma, J. E., & Lin, S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12040330 · Cited by 20
Update on Therapeutic Protein–Drug Interaction: Information in Labeling
Jing, X., Ji, P., Schrieber, S. J., Fletcher, E. P., & Sahajwalla, C. G. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00810-z · Cited by 19
The European Medicines Agency Experience With Pediatric Dose Selection
Manolis, E., Musuamba, F. T., & Karlsson, K. E. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1863 · Cited by 18
Mian, P., Nolan, B. E., van den Anker, J. N., Calsteren, K. V., Allegaert, K., Lakhi, N. A., & Dallmann, A. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.733520 · Cited by 18
Rostami‐Hodjegan, A., & Toon, S. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1654 · Cited by 17
Šegregur, D., Barker, R., Mann, J., Moir, A. J., Karlsson, Ε., Turner, D. B., Arora, S., & Dressman, J. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105750 · Cited by 17
Aksenov, S., Roberts, J. C., Mugundu, G. M., Mueller, K. T., Bhattacharya, I., & Tortorici, M. A. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2374 · Cited by 17
Lloyd, R. S., Hingle, M., Bloomer, J. C., Charles, S. J., Butler, J., Paul, A., Zhu, X., Miller, B. E., D'Amico, D., Donald, A., et al. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-02948-z · Cited by 13
Sahre, M. D., Milligan, L., Madabushi, R., Graham, R., Reynolds, K. S., Terzic, A., Benjamin, J. M., Burckart, G. J., Huang, S. M., Schuck, R. N., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2151 · Cited by 13
Lee, J., Yang, Y., Zhang, X., Fan, J., Grimstein, M., Zhu, H., & Wang, Y. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1819 · Cited by 13
Self-citationPape, E., Michel, D., Scala‐Bertola, J., Schiestel, T., Harlé, A., Bouchet, S., Contet, A., Pochon, C., & Gambier, N. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12895 · Cited by 12
European Regulatory Perspective on Pediatric Physiologically Based Pharmacokinetic Models
Cole, S. M., Hay, J. L., Luzon, E., Nordmark, A., & Rusten, I. S. (2017) · International Journal of Pharmacokinetics · doi:10.4155/ipk-2016-0025 · Cited by 12
Hepatic Impairment Physiologically Based Pharmacokinetic Model Development: Current Challenges
Han, A. N., Han, B. R., Zhang, T., & Heimbach, T. (2021) · Current Pharmacology Reports · doi:10.1007/s40495-021-00266-5 · Cited by 12
Self-citationLu, T., Fraczkiewicz, G., Salphati, L., Budha, N. R., Dalziel, G., Smelick, G. S., Morrissey, K. M., Davis, J. D., Jin, J. Y., & Ware, J. A. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12228 · Cited by 11
Salem, F., Johnson, T. N., Abduljalil, K., Tucker, G. T., & Rostami‐Hodjegan, A. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0284-0 · Cited by 9
Progress in Drug Development–Pediatric Dose Selection: Workshop Summary
Wang, J., van den Anker, J. N., & Burckart, G. J. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1828 · Cited by 7
Research works printed but not linked: 8
- FDA. M-CERSI Workshop: Assessing Changes in Pharmacokinetics of Drugs in Liver Disease. 2020.
- Rowland M, Tozer TN. Clinical pharmacokinetics and pharmacodynamics: concepts and applications Philadelphia : Wolters Kluwer Health/Lippincott William & Wilkins, 2011.
- Lin W, Yan J, Heimbach T, He H. Pediatric Physiologically Based Pharmacokinetic Model Development: Current Status and Challenges. J Pharm Sci. 2018;4:491–501.
- Dodd S, Kollipara S, Sanchez-Felix M, Kim H, Meng Q, Beato S, Heimbach T. Prediction of ARA/PPI Drug-Drug Interactions at the Drug Discovery and Development Interface. J Pharm Sci. 2019;108(1):87–101. · DOI
- Edlund H, Bellanti F, Liu H, Vishwanathan K, Tomkinson H, Ware J, Sharma S, Buil-Bruna N. Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP-5862, in patients with B-cell malignancies and in healthy subjects using a population pharmacokinetic approach. British Journal of Clinical Pharmacology;n/a(n/a).
- Miller BE, Mistry S, Smart K, Connolly P, Carpenter DC, Cooray H, Bloomer JC, Tal-Singer R, Lazaar AL. The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects. BMC Pharmacol Toxicol. 2015;16(1):18. · DOI
- Bloomer JC, Ambery C, Miller BE, Connolly P, Garden H, Henley N, Hodnett N, Keel S, Kreindler JL, Lloyd RS, Matthews W, Yonchuk J, Lazaar AL. Identification and characterisation of a salt form of Danirixin with reduced pharmacokinetic variability in patient populations. Eur J Pharm Biopharm. 2017;117:224–31. · DOI
- Keyvanjah K, Fang P, Cooke B, DiPrimeo D, Pearl J, Dyla S, Hunt D, Rubets I, Wong A, Martin D. A drug-drug interaction study evaluating the effect of multiple doses of ranitidine administered once daily or staggered twice daily on the pharmacokinetics and safety of neratinib in healthy subjects. JACCP journal of the american college of clinical pharmacy. 2018;1(2):123‐.
Cited by
Marques, L., Costa, B., Pereira, M., Silva, A., Santos, J., Saldanha, L., Silva, I., Magalhães, P., Schmidt, S., & Vale, N. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16030332 · Cited by 390
Deepika, D., & Kumar, V. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20043473 · Cited by 109
Malheiro, V., Santos, B., Figueiras, A., & Mascarenhas‐Melo, F. (2025) · Pharmaceuticals · doi:10.3390/ph18060788 · Cited by 101
In Silico ADME Methods Used in the Evaluation of Natural Products
Ancuceanu, R., Lascu, B. E., Drăgănescu, D., & Dinu, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081002 · Cited by 96
Wu, D., & Li, M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03373-0 · Cited by 60
Self-citation
Metadata
- Authors
- Lin, W., Chen, Y., Unadkat, J. D., Zhang, X., Wu, D., & Heimbach, T.
- Affiliations
- Janssen Research & Development (United States) (US)
- Genentech (US)
- University of Washington (US)
- United States Food and Drug Administration (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Zhang, Xinyuan
- Venue
- Pharmaceutical Research
- Published
- 2022-05-13
- Volume
- 39
- Issue
- 8
- Pages
- 1701-1731
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W4280544609
- Cited by
- 137
- References
- 173
- Citations by year
- 2026: 18 · 2025: 40 · 2024: 43 · 2023: 24 · 2022: 12
- FWCI
- 7.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- physiologically based pharmacokinetic modeling, physiologically based biopharmaceutics modeling, model-informed drug development, regulatory guidelines, model validation, drug-drug interactions, drug-metabolizing enzymes, drug transporters, pediatric dosing, renal dysfunction, liver dysfunction, pregnancy, proton pump inhibitors, acid-reducing agents
- MeSH terms
- Adolescent, Biopharmaceutics, Child, Computer Simulation, Drug Interactions, Humans, Infant, Newborn, Models, Biological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.